Article Type
Article
Changed
Thu, 03/31/2022 - 12:18
Display Headline
Cancer Data Trends 2022: Genitourinary Cancers

Click to view more from Cancer Data Trends 2022.

References

  1. Alba PR, Gao A, Lee KM, et al. Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing. JCO Clin Cancer Inform. 2021;5:1005-1014. doi:10.1200/CCI.21.00030 

  1. Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int. 2011;108(11):1684-1695. doi:10.1111/j.1464-410X.2010.10489.x 

  1. Hamdy FC, Donovan JL, Lane JA, et al, for the ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220 

  1. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141-1150. doi:10.1001/jama.2017.1652 

  1. Loeb S, Byrne N, Makarov DV, et al. Use of conservative management for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System from 2005-2015. JAMA. 2018;319(21):2231-2233. doi:10.1001/jama.2018.5616 

  1. Montgomery B, Rettig M, Kasten J, et al. The Precision Oncology Program for Cancer of the Prostate (POPCaP) network: a Veterans Affairs/Prostate Cancer Foundation Collaboration. Fed Pract. 2020;37(suppl 4):S48-S53. doi:10.12788/fp.0021 

  1. US Department of Veterans Affairs. Bladder cancer: know the signs. VAntage Point. Published June 15, 2021. Accessed December 13, 2021. https://blogs.va.gov/VAntage/90105/bladder-cancer-know-signs/ 

  1. Caputo JM, Moran G, Muller B, et al. The management of newly-diagnosed non-muscle invasive bladder cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration. Mil Med. 2020;185(1-2):276-281. doi:10.1093/milmed/usz166 

  1. US Department of Veterans Affairs. Agent Orange exposure and VA disability compensation. Updated June 15, 2021. Accessed December 13, 2021. https://www.va.gov/disability/eligibility/hazardous-materials-exposure/agent-orange/ 

  1. Bhanegaonkar A, Pandya S, Zheng Y, et al. Real-world outcomes among US Veterans Health Administration patients newly diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy. Adv Ther. 2021;38:2644-2661. doi:10.1007/s12325-021-01657-2 

  1. Macleod LC, Tykodi SS, Holt SK, et al. Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era. Urology. 2015;86(2):262-268. doi:10.1016/j.urology.2015.05.008

Publications
Federal Practitioner

Click to view more from Cancer Data Trends 2022.

Click to view more from Cancer Data Trends 2022.

References

  1. Alba PR, Gao A, Lee KM, et al. Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing. JCO Clin Cancer Inform. 2021;5:1005-1014. doi:10.1200/CCI.21.00030 

  1. Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int. 2011;108(11):1684-1695. doi:10.1111/j.1464-410X.2010.10489.x 

  1. Hamdy FC, Donovan JL, Lane JA, et al, for the ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220 

  1. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141-1150. doi:10.1001/jama.2017.1652 

  1. Loeb S, Byrne N, Makarov DV, et al. Use of conservative management for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System from 2005-2015. JAMA. 2018;319(21):2231-2233. doi:10.1001/jama.2018.5616 

  1. Montgomery B, Rettig M, Kasten J, et al. The Precision Oncology Program for Cancer of the Prostate (POPCaP) network: a Veterans Affairs/Prostate Cancer Foundation Collaboration. Fed Pract. 2020;37(suppl 4):S48-S53. doi:10.12788/fp.0021 

  1. US Department of Veterans Affairs. Bladder cancer: know the signs. VAntage Point. Published June 15, 2021. Accessed December 13, 2021. https://blogs.va.gov/VAntage/90105/bladder-cancer-know-signs/ 

  1. Caputo JM, Moran G, Muller B, et al. The management of newly-diagnosed non-muscle invasive bladder cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration. Mil Med. 2020;185(1-2):276-281. doi:10.1093/milmed/usz166 

  1. US Department of Veterans Affairs. Agent Orange exposure and VA disability compensation. Updated June 15, 2021. Accessed December 13, 2021. https://www.va.gov/disability/eligibility/hazardous-materials-exposure/agent-orange/ 

  1. Bhanegaonkar A, Pandya S, Zheng Y, et al. Real-world outcomes among US Veterans Health Administration patients newly diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy. Adv Ther. 2021;38:2644-2661. doi:10.1007/s12325-021-01657-2 

  1. Macleod LC, Tykodi SS, Holt SK, et al. Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era. Urology. 2015;86(2):262-268. doi:10.1016/j.urology.2015.05.008

References

  1. Alba PR, Gao A, Lee KM, et al. Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing. JCO Clin Cancer Inform. 2021;5:1005-1014. doi:10.1200/CCI.21.00030 

  1. Carter HB. Management of low (favourable)-risk prostate cancer. BJU Int. 2011;108(11):1684-1695. doi:10.1111/j.1464-410X.2010.10489.x 

  1. Hamdy FC, Donovan JL, Lane JA, et al, for the ProtecT Study Group. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415-1424. doi:10.1056/NEJMoa1606220 

  1. Chen RC, Basak R, Meyer AM, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate cancer. JAMA. 2017;317(11):1141-1150. doi:10.1001/jama.2017.1652 

  1. Loeb S, Byrne N, Makarov DV, et al. Use of conservative management for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System from 2005-2015. JAMA. 2018;319(21):2231-2233. doi:10.1001/jama.2018.5616 

  1. Montgomery B, Rettig M, Kasten J, et al. The Precision Oncology Program for Cancer of the Prostate (POPCaP) network: a Veterans Affairs/Prostate Cancer Foundation Collaboration. Fed Pract. 2020;37(suppl 4):S48-S53. doi:10.12788/fp.0021 

  1. US Department of Veterans Affairs. Bladder cancer: know the signs. VAntage Point. Published June 15, 2021. Accessed December 13, 2021. https://blogs.va.gov/VAntage/90105/bladder-cancer-know-signs/ 

  1. Caputo JM, Moran G, Muller B, et al. The management of newly-diagnosed non-muscle invasive bladder cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration. Mil Med. 2020;185(1-2):276-281. doi:10.1093/milmed/usz166 

  1. US Department of Veterans Affairs. Agent Orange exposure and VA disability compensation. Updated June 15, 2021. Accessed December 13, 2021. https://www.va.gov/disability/eligibility/hazardous-materials-exposure/agent-orange/ 

  1. Bhanegaonkar A, Pandya S, Zheng Y, et al. Real-world outcomes among US Veterans Health Administration patients newly diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy. Adv Ther. 2021;38:2644-2661. doi:10.1007/s12325-021-01657-2 

  1. Macleod LC, Tykodi SS, Holt SK, et al. Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era. Urology. 2015;86(2):262-268. doi:10.1016/j.urology.2015.05.008

Publications
Federal Practitioner
Publications
Federal Practitioner
Article Type
Article
Display Headline
Cancer Data Trends 2022: Genitourinary Cancers
Display Headline
Cancer Data Trends 2022: Genitourinary Cancers
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 03/14/2022 - 11:30
Un-Gate On Date
Mon, 03/14/2022 - 11:30
Use ProPublica
CFC Schedule Remove Status
Mon, 03/14/2022 - 11:30
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media